Dose Comparison Study of Intravenous ICG Dose in Lung Malignant Tumor Localization Method Using Fluorescence Spectroscopy Syste - Identification of Lung Malignant Tumors with a spectral device using the ICG intravenous administration method

Kato Tatsuya0 个研究点目标入组 60 人开始时间: 2023年9月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet all of the following criteria are eligible
•(1) Male and female patients aged 20 years or older at the time of consent
•(2) Patients with a preoperative diagnosis of primary lung cancer (or suspected primary lung cancer)
•or metastatic lung tumor (or suspected metastatic lung tumor)
•(3) Patients whose tumor diameter on CT is 1 cm or greater and whose tumor is located within 2 cm
•in depth from the lung surface
•(4) Patients who have received a thorough explanation of their participation in this study, and who
•have given their free and voluntary written consent based on a thorough understanding of the situati

•Patients who fall under any one of the following categories shall be excluded.
•(1) Age less than 20 years old at the time of consent
•(2) Patients with a history of allergy to ICG, iodineor contrast media (because ICG contains a small a
•mount of iodine)
•(3) Patients with interstitial pneumonia or pulmonary fibrosis evident on chest CT
•(4) Pregnant or lactating mothers
•(5) Patients who are abstinent or unable to use effective contraceptive methods during the period of
•participation in the study
•(6) Patients who have difficulty in oral intake
•(7) Patients with obvious hepatic or cardiac dysfunction
•(8) Patients with dementia and others who need to give their consent
•(9) Other patients deemed inappropriate as resear
•ch subjects by the principal investigator or subinvestigator.

发起方

Kato Tatsuya